Effects of coenzyme Q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with non-alcoholic fatty liver disease

Elnaz Jafarvand,Manouchehr Khoshbaten,Beytollah Alipour,Mahdieh Abbasalizad Farhangi

doi:10.3329/bjp.v11i1.24513

Elnaz Jafarvand, Manouchehr Khoshbaten + Show 2 more

Open Access

https://doi.org/10.3329/bjp.v11i1.24513

Copy DOI

Abstract

<p class="Abstract">This randomized double-blind placebo-controlled trial was conducted on 41 patients with non-alcoholic fatty liver disease. Patients in intervention group received 100 mg/day coenzyme Q10 (CoQ10) for four weeks. There was a significant reduction in waist circumference and aspartate aminotransferase concentrations after CoQ10 supplementation (p&lt;0.05). Dietary fiber was in negative correlation with change in serum alanine aminotransferase (ALT) concentrations (r = -410, p = 0.04), and dietary fat intake was in positive relation with serum triglyceride (r = 463, p = 0.04) and in negative relation with serum high-density lipoprotein cholesterol (HDL-C) (r = -533, p = 0.02) in CoQ10-treated group. CoQ10 supplement is able to reduce central obesity and improve liver function in non-alcoholic fatty liver disease. Dietary factors were also significant determinants of change in liver-specific enzyme ALT and lipid profile in these patients. Further trials with higher dose of CoQ10 and longer treatment periods are warranted to better clarify these findings.</p><p> </p>

Highlights

Non-alcoholic fatty liver disease is defined as the accumulation of fat mainly triglyceride in hepatic cells exceeding 5-10% of liver weight (Chalasani et al, 2012)
The oxidative stress is implicated as a key factor contributing to liver damage in patients suffering from nonalcoholic fatty liver disease (Madan et al, 2006)
The main treatments are based on the management of insulin resistance and oxidative stress

Summary

Introduction

Non-alcoholic fatty liver disease is defined as the accumulation of fat mainly triglyceride in hepatic cells exceeding 5-10% of liver weight (Chalasani et al, 2012). The prevalence in the general population and in obese individuals is 20–30% and 67–75% respectively (Browning et al, 2004). It is the third cause of liver transplant and is associated with obesity, metabolic syndrome, insulin resistance, type 2 diabetes mellitus and dyslipidemia (Chalasani et al, 2012; Farhangi et al, 2013; Jahangiry et al, 2014). The main treatments are based on the management of insulin resistance and oxidative stress. Numerous evidences suggest that antioxidants such as vitamin E, vitamin C, α-tocopherol and betaine are capable in improving clinical and histological features of non-alcoholic fatty liver disease (Mouzaki and Allard, 2012)

Objectives

Methods

Results

Discussion

Conclusion